CN109890827A - 螺环化合物 - Google Patents

螺环化合物 Download PDF

Info

Publication number
CN109890827A
CN109890827A CN201780067175.6A CN201780067175A CN109890827A CN 109890827 A CN109890827 A CN 109890827A CN 201780067175 A CN201780067175 A CN 201780067175A CN 109890827 A CN109890827 A CN 109890827A
Authority
CN
China
Prior art keywords
cancer
compound
pharmaceutically acceptable
acceptable salt
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780067175.6A
Other languages
English (en)
Chinese (zh)
Inventor
黄琴华
穆罕默德·卡赫拉曼
凯文·杜安·邦克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeno Royalty Milestone Co Ltd
Original Assignee
Zeno Royalty Milestone Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeno Royalty Milestone Co Ltd filed Critical Zeno Royalty Milestone Co Ltd
Publication of CN109890827A publication Critical patent/CN109890827A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780067175.6A 2016-10-05 2017-10-03 螺环化合物 Pending CN109890827A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404668P 2016-10-05 2016-10-05
US62/404,668 2016-10-05
PCT/US2017/054865 WO2018067512A1 (en) 2016-10-05 2017-10-03 Spirocyclic compounds

Publications (1)

Publication Number Publication Date
CN109890827A true CN109890827A (zh) 2019-06-14

Family

ID=61831517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780067175.6A Pending CN109890827A (zh) 2016-10-05 2017-10-03 螺环化合物

Country Status (13)

Country Link
US (2) US10934304B2 (https=)
EP (1) EP3523306A4 (https=)
JP (2) JP6949952B2 (https=)
KR (1) KR20190075931A (https=)
CN (1) CN109890827A (https=)
AU (1) AU2017339890A1 (https=)
BR (1) BR112019005305A2 (https=)
CA (1) CA3037064A1 (https=)
IL (1) IL265752A (https=)
MX (1) MX2019003938A (https=)
RU (1) RU2019107667A (https=)
TW (1) TW201817732A (https=)
WO (1) WO2018067512A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
HUE049481T2 (hu) 2015-04-03 2020-09-28 Recurium Ip Holdings Llc Spirociklusos vegyületek
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
IL281212B2 (en) * 2018-09-07 2023-12-01 Merck Patent Gmbh 5-Morpholin-4-yl-pyrazolo[4,3-B]pyridine derivatives and their use
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) * 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2025096858A1 (en) * 2023-10-31 2025-05-08 C4 Therapeutics, Inc. Compounds for the degradation of mutant braf

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370784A (zh) * 2005-12-13 2009-02-18 先灵公司 为胞外信号调节激酶抑制剂的新颖化合物
WO2013033059A1 (en) * 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
US20140135335A1 (en) * 2012-11-09 2014-05-15 Bristol-Myers Squibb Company Spiro bicyclic oxalamide compounds for the treatment of hepatitis c
CN105732636A (zh) * 2014-12-30 2016-07-06 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2016161160A1 (en) * 2015-04-03 2016-10-06 Kalyra Pharmaceuticals, Inc. Spirocyclic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3305776T (lt) * 2004-05-14 2020-01-10 Vertex Pharmaceuticals Incorporated Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais
WO2008063609A2 (en) 2006-11-17 2008-05-29 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
WO2008156739A1 (en) * 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
US20110166124A1 (en) 2008-07-23 2011-07-07 Mccormick Kevin D Tricyclic spirocycle derivatives and methods of use
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
KR102243637B1 (ko) 2013-03-14 2021-04-26 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 진통 화합물
WO2016106009A1 (en) 2014-12-22 2016-06-30 Eli Lilly And Company Erk inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101370784A (zh) * 2005-12-13 2009-02-18 先灵公司 为胞外信号调节激酶抑制剂的新颖化合物
WO2013033059A1 (en) * 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
US20140135335A1 (en) * 2012-11-09 2014-05-15 Bristol-Myers Squibb Company Spiro bicyclic oxalamide compounds for the treatment of hepatitis c
CN105732636A (zh) * 2014-12-30 2016-07-06 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
WO2016161160A1 (en) * 2015-04-03 2016-10-06 Kalyra Pharmaceuticals, Inc. Spirocyclic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMES F. BLAKE, ET AL.: "Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development", 《JOURNAL OF MEDICINAL CHEMISTRY》 *

Also Published As

Publication number Publication date
JP6949952B2 (ja) 2021-10-13
US10934304B2 (en) 2021-03-02
BR112019005305A2 (pt) 2019-07-02
JP2019534261A (ja) 2019-11-28
WO2018067512A1 (en) 2018-04-12
TW201817732A (zh) 2018-05-16
AU2017339890A1 (en) 2019-04-11
MX2019003938A (es) 2019-06-10
US20210115058A1 (en) 2021-04-22
CA3037064A1 (en) 2018-04-12
RU2019107667A (ru) 2020-11-06
KR20190075931A (ko) 2019-07-01
WO2018067512A8 (en) 2018-11-01
US20200207776A1 (en) 2020-07-02
EP3523306A1 (en) 2019-08-14
RU2019107667A3 (https=) 2021-01-27
NZ751398A (en) 2021-03-26
JP2021193138A (ja) 2021-12-23
EP3523306A4 (en) 2020-05-06
IL265752A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
JP6949952B2 (ja) スピロ環化合物
TWI848954B (zh) 作為hpk1抑制劑的吡咯並[2,3-b]吡啶或吡咯並[2,3-b]吡嗪及其用途
TWI794297B (zh) 化合物用於製備與第二抗-呼吸道融合性病毒試劑組合使用以治療呼吸道細胞融合病毒感染的藥物之用途及醫藥組合物
EP3828179A1 (en) Cyanopyrrolidines as dub modulators
TWI705067B (zh) 螺環化合物
JP2018524367A (ja) 癌の処置のためのｄｕｂ阻害剤としてのシアノピロリジン
JP2026506002A (ja) Ｓｏｓ１阻害剤及び抗がん薬を含む、がんの処置のための医薬組成物
TW202317106A (zh) 作為egfr抑制劑之取代胺基吡啶化合物
CN101663276A (zh) 用作激酶抑制剂的2-氨基吡啶衍生物
NZ751398B2 (en) Spirocyclic compounds
HK1256671B (en) Spirocyclic compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: California, USA

Applicant after: Ricoram IP Holding Co., Ltd

Address before: California, USA

Applicant before: Zeno Royalty Milestone Co., Ltd.

CB02 Change of applicant information
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190614

WD01 Invention patent application deemed withdrawn after publication